<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151403">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01964989</url>
  </required_header>
  <id_info>
    <org_study_id>V118_05</org_study_id>
    <secondary_id>2012-000218-12</secondary_id>
    <nct_id>NCT01964989</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.</brief_title>
  <official_title>A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to &lt; 72 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Spain:  Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</authority>
    <authority>Italy: AGENZIA ITALIANA DEL FARMACO (AIFA)</authority>
    <authority>Russian Federation: Ministry of Health of the Russian Federation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus
      Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to &lt;72 Months
      of Age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>RT-PCR-confirmed influenza cases in all subjects</measure>
    <time_frame>Weekly from Day 1 up to 180 days after the last vaccination or until the end of the influenza season, whichever is longer</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relative efficacy of aQIV compared to comparator vaccine as determined by RT-PCR-confirmed influenza</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with solicited AEs</measure>
    <time_frame>For 7 days following each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate safety and tolerability of each study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with all unsolicited AEs</measure>
    <time_frame>vaccine-naïve subjects: Day 1 to Day 50; vaccine non-naïve subjects: Day 1 to 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, new onset of chronic disease, Adverse Event of Special Interest (AESI) and all medications associated</measure>
    <time_frame>12 months after last vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hazard ratios calculated: Occurrence of RT-PCR and culture-confirmed influenza cases in all subjects</measure>
    <time_frame>occurring at &gt;21 days and ≤ 180 days after the last vaccination  or until the end of the influenza season, whichever is longer,</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy:
The relative efficacy of aQIV compared to comparator as determined by the proportion of subjects with culture-confirmed influenza The relative efficacy of aQIV compared to comparator as determined by RT-PCR-confirmed and culture-confirmed influenza in age subgroups, in children at risk of influenza, and in children depending on previous vaccination status The early relative efficacy of aQIV compared to comparator as determined by RT-PCR-confirmed influenza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hazard ratios calculated: Early occurrence of RT-PCR-confirmed influenza cases in all subjects</measure>
    <time_frame>on first-occurrence of RT-PCR-confirmed influenza cases</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean HI titer (GMT)</measure>
    <time_frame>vaccine naïve subjects: on Day 1, Day 29, Day 50 and Day 209, vaccine non-naïve subjects: on Day 1, Day 22 and Day 181</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity:
To compare antibody responses between aQIV and comparator (including assessment of non-inferiority and superiority)
The endpoints for immunogenicity measured in aQIV and comparator as determined by HI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio (GMR)</measure>
    <time_frame>vaccine naïve subjects on Day 29/Day 1, Day 50/Day 1 and Day 209/Day 1, vaccine non-naïve: Day 22/Day 1 and Day 181/Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vaccine naïve and non-naïve subjects achieving seroconversion</measure>
    <time_frame>vaccine naïve subjects: on Day 29 and Day 50, vaccine non-naïve subjects: on Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with HI titer ≥ 1:40</measure>
    <time_frame>vaccine naïve subjects on Day 29, Day 50 and Day 209, vaccine non-naïve: Day 22 and Day 181</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with higher HI titer thresholds</measure>
    <time_frame>vaccine naïve subjects on Day 29, Day 50 and Day 209, vaccine non-naïve: Day 22 and Day 181</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with solicited AEs</measure>
    <time_frame>for 7 days following each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety:
To evaluate safety and tolerability of each study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with all unsolicited AEs</measure>
    <time_frame>from Day 1 to Day 50, vaccine non-naïve subjects from Day 1 to Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, New Onset of Chronic Disease (NOCD), Adverse Events of Special Interest(AESI) and all medications associated</measure>
    <time_frame>12 months after last vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of subjects with a medical visit for respiratory illness associated with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health Economic Outcome:
To evaluate healthcare utilization and health economic outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of employment days missed by parent(s)/guardian(s) of subjects with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of days of daycare, school or preschool missed by subjects associated with RT-PCR-confirmed influenza</measure>
    <time_frame>within a window of 14 days after ILI-onset</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10616</enrollment>
  <condition>Influenza Virus</condition>
  <arm_group>
    <arm_group_label>aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-adjuvanted comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</intervention_name>
    <description>1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to &lt;36 months, 0.5 ml: ≥36 months to &lt;72 months</description>
    <arm_group_label>aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted Trivalent Influenza Vaccine (TIV) /  Quadrivalent Influenza Vaccine (QIV)</intervention_name>
    <description>1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to &lt;36 months, 0.5 ml: ≥36 months to &lt;72 months</description>
    <arm_group_label>non-adjuvanted comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children, males and females, healthy or at high risk of complications from influenza,
             between ≥6 months to &lt;72 months of age

          -  Documented consent provided by the subject's parent(s)/legal guardian(s)

          -  Subjects and/or subject's parent(s)/legal guardian(s) able to comply with all study
             procedures.

        Exclusion Criteria:

          -  Children with history of allergy to vaccine components.

          -  Additional eligibility criteria may be discussed by contacting the site
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Drug Information Services</last_name>
    <phone>+1 800 244 7668</phone>
  </overall_contact>
  <location>
    <facility>
      <name>222,Radiant Research, Inc.,2081 W. Frye Road</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>267,Clinical Research Connections,802 N. Illinois St.</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>213,Center for Clinical Trials of San Gabriel,14514 Ramona Blvd, Unit 3</name>
      <address>
        <city>Baldwin Park</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>238,CENTER FOR CLINICAL TRIALS OF SAN GABRIEL,1400 N. Hacienda Blvd</name>
      <address>
        <city>La Puente</city>
        <state>California</state>
        <zip>91774</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>202,Center for Clinical Trials, LLC,16660 Paramount Blvd</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>250,California Research Foundation,2800 Third Avenue</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>243,Colorado Springs Health Partners -Briargate,2405 Research Parkway</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>249,Radiant Research, Inc,12015 E. 46th Ave</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>229,Boca Raton Clinical Research,600 South Dixie Highway</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>224,Accelovance, Inc,1600 W. Eau Gallie Blvd.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>234,Sunshine Research Center,486 Fisherman St.</name>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <zip>33054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>261,Pediatric and Adolescent Medicine,120 Stonebridge Pkwy</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>268,Accelovance, Inc,222 NE Monroe St.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>209,Heartland Research,1601 State Street</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>210,Heartland Research Associates, LLC,700 Medical Center Dr</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>211,Heartland Research Associates, LLC,3730 N. Ridge Rd</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>207,Bluegrass Clinical Research, Inc,5512 Bardstown Road</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>265,ACC Pediatric Research,1025 Hwy 80E</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>225,Benchmark Research,3800 Houma Blvd.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>233,MedPharmics, LLC,3800 Houma Blvd</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>221,Meridian Clinical Research,1103 Galvin Road South</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>219,Clinical Research Advantage - Pediatric Partners, LLC,750 E 29th St</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>244,Clinical Research Center of Nevada,600 Whitney Ranch Dr.</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>255,United Medical Associates,1290 Upper Front Street</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>264,SUNY Upstate Medical University,Department of Pediatrics</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>240,Radiant Research, Inc,530 S. Main Street</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>245,Dayton Clinical Research,1100 Salem Avenue</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>256,Oklahoma State University - Center for Health Sciences,Houston Center Pediatrics</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>270,Fay West Family Practice,109 Crossroads Road</name>
      <address>
        <city>Scottsdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>220,Radiant Research,1657 E. Greenville St</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>232,PMG Research of Charleston,2061 Hwy 52 S.</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>208,Benchmark Research,1015 East 32nd St.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>217,Benchmark Research,4504 Boat Club Road</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>214,Benchmark Research,3555 Knickerbocker Rd</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>260,Pediatric Healthcare of NW Houston,13406 Medical Complex Dr</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>212,Foothill Family Clinic South,6360 South 3000 East</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>246,Jean Brown Research,1045 East 3900 South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>236,J Lewis Research Inc Foothill Family Clinic,2295 Foothill Dr</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>271,Jordan Ridge Kids &amp; Teens,8822 S. Redwood Road</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>201,Advanced Clinical Research,3590 W. 9000 S</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>251,Pi-Coor Clinical Research, L.L.C.,8982 Fern Park Drive</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>180,SKDS Research Inc,679 Davis Dr</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>184, Medicor Research 359 Riverside Dr.</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>182, Dr. Anil K. Gupta Medicine Professional Corporation 1620 Albion Rd</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>183, Centre de recherche d CHU de Québec 2400 avenue d'Estimauville</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>001,Espoo Vaccine Research Clinic,Ison Omenan toimistotorni, 7. krs</name>
      <address>
        <city>Espoo</city>
        <zip>FI-02230</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>002,Helsinki East Vaccine Research Clinic,Itäkeskuksen kauppakeskus, Agenttitalo</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00930</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>003,Helsinki South Vaccine Research Clinic,Vuorikatu 18, 3rd floor</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>004,Järvenpää Vaccine Research Clinic,Yhteiskouluntie 17</name>
      <address>
        <city>Järvenpää</city>
        <zip>FIN-04400</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>005,Kokkola Vaccine Research Clinic,Rantakatu 7</name>
      <address>
        <city>Kokkola</city>
        <zip>FI-67100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>006,Oulu Vaccine Research Clinic,Kiviharjunlenkki 6</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>007,Pori Vaccine Research Clinic,Yrjönkatu 23</name>
      <address>
        <city>Pori</city>
        <zip>FI-28100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>008,Seinäjoki Vaccine Research Clinic,Keskuskatu 6</name>
      <address>
        <city>Seinäjoki</city>
        <zip>FI-60100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>009,Tampere Vaccine Research Clinic,Pinninkatu 47, 1st floor</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>010,Turku Vaccine Research Clinic,Lemminkäisenkatu 14-18 B, 4th floor</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>011,Vantaa Vaccine Research Clinic,Asematie 11 A 16</name>
      <address>
        <city>Vantaa</city>
        <zip>FIN-01300</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>children</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
